A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysisCapsule Summary

• Main Authors: Norito Katoh, MD, PhD (Author), Yukihiro Ohya, MD, PhD (Author), Hiroyuki Murota, MD, PhD (Author), Masanori Ikeda, MD, PhD (Author), Xiaofei Hu, PhD (Author), Kimitoshi Ikeda, PhD (Author), John Liu, MD, MS (Author), Takuya Sasaki (Author), Alvina D. Chu, MD (Author), Henrique D. Teixeira, PhD, MBA (Author), Hidehisa Saeki, MD, PhD (Author)
• Format: Book
• Published: Elsevier, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Systemic atopic dermatitis treatments that have acceptable safety are needed. Objective: To evaluate the safety of the oral Janus kinase inhibitor upadacitinib in combination with topical corticosteroids (TCSs) for the treatment of atopic dermatitis. Methods: In this phase 3, double-blin...